| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/06/2003 | WO2001066139A9 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 02/06/2003 | WO2001064874A9 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/06/2003 | US20030028923 Nucleotide sequences coding enzymatic polypeptide for use in the generation of disease resistant plants |
| 02/06/2003 | US20030028077 Cardiac disease treatment and device |
| 02/06/2003 | US20030028006 Cytokine receptor common gamma chain like |
| 02/06/2003 | US20030027983 Transport protein for use in the treatment of blood, hypertensive and epileptic disorders |
| 02/06/2003 | US20030027869 Amine compounds and inhibiting neurotransmitter reuptake |
| 02/06/2003 | US20030027867 Use of R-NSAID compounds for anti-HIV treatment |
| 02/06/2003 | US20030027847 Carboxyformylacetamide derivatives for treatment of AIDS or ARC |
| 02/06/2003 | US20030027844 Component a): one or more conventional anti-ulcer products; component b): organic compounds containing the -ONO2 function, or inorganic compounds containing the -NO group, that are nitric oxide donors |
| 02/06/2003 | US20030027839 Farnesyl protein transferase inhiitors for treating breast cancer |
| 02/06/2003 | US20030027835 Trimebutine, N-desmethyltrimebutine, their metabolites or their stereoisomers and an opioid analgesic for treating pain or nociception. |
| 02/06/2003 | US20030027824 Pyrazolopyrimidinones for the treatment of female sexual dysfunction |
| 02/06/2003 | US20030027818 Treatment of cancers |
| 02/06/2003 | US20030027817 Combination therapy for treatment of bipolar disorders |
| 02/06/2003 | US20030027811 Compositions containing alpha-2-adrenergic agonist components |
| 02/06/2003 | US20030027806 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 02/06/2003 | US20030027802 Methods for preventing antipsychotic-induced weight gain |
| 02/06/2003 | US20030027799 As anticancer agents |
| 02/06/2003 | US20030027786 Lipase inhibiting composition |
| 02/06/2003 | US20030027785 Administering to a subject a purinergic receptor agonist in an amount therapeutically effective to alter the amount or formulation of synovial fluids |
| 02/06/2003 | US20030027772 Composition containing at least one inhibitor of the enzyme 3-beta-HSD |
| 02/06/2003 | US20030027749 For use in therapy, and diagnostic assays |
| 02/06/2003 | US20030027748 For therapy of diabetes |
| 02/06/2003 | US20030027746 Useful in the development of human therapeutics and diagnostic formulations |
| 02/06/2003 | US20030027744 Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye |
| 02/06/2003 | US20030027253 Nucleotides equences codin polypeptide for use in the treatment of cancer |
| 02/06/2003 | US20030027248 Human cDNAs and proteins and uses thereof |
| 02/06/2003 | US20030027243 Screening or testing fungicide; obtain fungal protein sample, incubate with test modulator, monitor interaction between fungicide and protein, adjustment in protein activity indicate fungicide |
| 02/06/2003 | US20030027230 Detection of antiproliferative agents for treatment of ovarian cancer; obtain cells, incubate with modulator, monitor cells for reduction in cancer activity, reduction in cancer activity indicates antiproliferative agents |
| 02/06/2003 | US20030027198 Nucleotide sequences coding polypeptide for use in the treatment of tumors |
| 02/06/2003 | US20030027188 SLC7s as modifiers of the p53 pathway and methods of use |
| 02/06/2003 | US20030027164 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain |
| 02/06/2003 | US20030027161 Human cDNAs and proteins and uses thereof |
| 02/06/2003 | US20030027151 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of bone disorders |
| 02/06/2003 | US20030027130 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of viral diseases |
| 02/06/2003 | US20030026862 (+)-Cycloolivil as antioxidant obtained from a new natural source namely stereospermum personatum |
| 02/06/2003 | US20030026838 Administering antagonist and antagonist removal drug |
| 02/06/2003 | US20030026820 Use of a compositon containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of a sensitive or intolerant skin |
| 02/06/2003 | US20030026803 Compositions for inhibiting macrophage activity |
| 02/06/2003 | US20030026801 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 02/06/2003 | US20030026796 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase |
| 02/06/2003 | CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs) |
| 02/06/2003 | CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a |
| 02/06/2003 | CA2454803A1 Probiotic bifidobacterium strains |
| 02/06/2003 | CA2454802A1 Novel class ii cytokine receptors and uses thereof |
| 02/06/2003 | CA2454562A1 Method of improving cognitive function |
| 02/06/2003 | CA2450073A1 Compositions and methods for modulating blood-brain barrier transport |
| 02/06/2003 | CA2448722A1 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
| 02/05/2003 | EP1281962A1 Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and an SH3 domain comprising peptide |
| 02/05/2003 | EP1281775A2 Identification and use of molecules implicated in pain |
| 02/05/2003 | EP1281702A2 Calcium receptor active molecules |
| 02/05/2003 | EP1281404A2 Use of antibodies against the urokinase receptor |
| 02/05/2003 | EP1281397A1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 02/05/2003 | EP1281396A2 Skin vitalizing composition for external use anti-aging preparation |
| 02/05/2003 | EP1280932A1 Interfering with telomere maintenance in treatment of diseases |
| 02/05/2003 | EP1280924A2 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| 02/05/2003 | EP1280921A1 Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy |
| 02/05/2003 | EP1280918A2 Lipid metabolism enzymes |
| 02/05/2003 | EP1280911A2 Regulatory nucleic acid sequences of the ABC1 gene |
| 02/05/2003 | EP1280905A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene carboxy terminal peptides |
| 02/05/2003 | EP1280904A2 Pain signaling molecules |
| 02/05/2003 | EP1280903A2 Ph domain-interacting protein |
| 02/05/2003 | EP1280898A1 Modified es cells and es cell-specific gene |
| 02/05/2003 | EP1280897A2 Regulation of nf-at interacting protein nip 45 variant |
| 02/05/2003 | EP1280896A2 Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof |
| 02/05/2003 | EP1280891A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase |
| 02/05/2003 | EP1280827A1 Agonists/antagonists of the gpr56 receptor as appetite control agents |
| 02/05/2003 | EP1280826A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| 02/05/2003 | EP1280823A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/05/2003 | EP1280821A1 Dna molecules encoding ligand gated ion channels from dermacentor variabilis |
| 02/05/2003 | EP1280777A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/05/2003 | EP1280604A1 Media milling |
| 02/05/2003 | EP1280572A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280571A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280570A2 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280569A1 Delivery systems for treatment of vascular disease |
| 02/05/2003 | EP1280568A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280556A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 02/05/2003 | EP1280555A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist |
| 02/05/2003 | EP1280554A2 A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal |
| 02/05/2003 | EP1280547A2 Mast cell regulation |
| 02/05/2003 | EP1280546A1 Method and composition for the treatment of angiogenesis |
| 02/05/2003 | EP1280536A2 Method for treating retinal degeneration with purinergic receptor agonists |
| 02/05/2003 | EP1280533A2 Aldosterone antagonist composition for release during aldosterone acrophase |
| 02/05/2003 | EP1280531A1 Local anesthetic methods and kits |
| 02/05/2003 | EP1280529A2 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists |
| 02/05/2003 | EP1280528A2 R-eliprodil for treating glaucoma |
| 02/05/2003 | EP1280527A2 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 02/05/2003 | EP1280518A2 Liposome drug delivery |
| 02/05/2003 | EP1280516A1 Method for transdermal or intradermal delivery of molecules |
| 02/05/2003 | EP1280512A2 Delivery systems for treatment of vascular disease |
| 02/05/2003 | EP1280420A1 Natural vegetable oil concentrated in unsaponifiable matters as food ingredient |
| 02/05/2003 | EP1200101A4 Methods for transdifferentiation of body tissues |
| 02/05/2003 | EP1104294A4 Compositions and methods of treating abnormal cell proliferation |
| 02/05/2003 | EP0996429B1 Solid state solutions and dispersions of poorly water soluble drugs |
| 02/05/2003 | EP0841904B1 Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors |
| 02/05/2003 | EP0841903B1 Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole |
| 02/05/2003 | EP0802782B1 Prophylactic and therapeutic treatment of skin sensitization and irritation |
| 02/05/2003 | EP0794787B1 Compositions for the treatment of parasitic and fungal infections |